Popular Trials
Behavioural Intervention
Electro-acupuncture + TES for Retinitis Pigmentosa
This trial is testing a treatment called transcorneal electrical stimulation for people with retinitis pigmentosa, a condition that leads to gradual vision loss. The treatment uses small electrical currents applied to the eye to improve blood flow and stimulate retinal cells, which may help slow down vision loss. Transcorneal electrical stimulation has shown several improvements in visual function in previous studies and is currently offered by several companies.
Stem Cell Therapy
Stem Cells for Retinal Disease
This trial is testing if injecting special cells from bone marrow into the eye is safe and possible for patients who are permanently blind due to retinal diseases. The hope is that these cells can help fix the damaged parts of their eyes.
Gene Therapy
Gene Therapy with Light-Stimulating Glasses for Retinitis Pigmentosa
This trial is testing a new gene therapy injected into the eye and special light-stimulating glasses for patients with a specific type of vision loss called non-syndromic Retinitis Pigmentosa. The gene therapy aims to fix genetic problems in the eye, while the glasses help activate the treated cells. Gene therapy has shown promise in treating retinal diseases.
Cell Therapy
hRPC for Retinitis Pigmentosa
This trial tests a new cell therapy where special cells are injected into the eye to help people with retinitis pigmentosa, a disease that causes vision loss. The goal is to see if these cells can repair or replace damaged parts of the eye.
Popular Filters
Trials for RP Patients
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Antisense Oligonucleotide
Ultevursen for Vision Impairments
This trial tests a drug called ultevursen, which is injected into the eye, for patients with a specific genetic form of Retinitis Pigmentosa. The drug targets and modifies the genetic mutation causing their vision loss.
Phosphodiesterase Type 5 (PDE5) Inhibitor
Sildenafil for Choroidal Ischemia
This trial is testing if Sildenafil can help patients with certain eye conditions by improving blood flow in the eye. The goal is to slow down vision loss and reduce the need for frequent treatments. Sildenafil, commonly known as Viagra, is primarily used to treat erectile dysfunction but has been studied for its effects on ocular blood flow and potential neuroprotective benefits in various eye conditions.
Stem Cell Therapy
Stem Cell Implantation for Retinitis Pigmentosa
This trial is testing if introducing special cells into the eye is safe for patients with vision loss. The cells might help protect and support the existing nerve cells in the eye, potentially slowing down or stopping vision loss.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.
Trials for PR Positive Patients
4D-125 for Retinitis Pigmentosa
This trial tests a new eye injection treatment for males with a genetic eye disease. The treatment replaces a faulty gene with a healthy one to help stop or slow down the disease. Gene therapy has been extensively studied and shows promise for treating genetic eye diseases by delivering functional genes to replace faulty ones.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
This trial is testing a new treatment for people with a genetic eye disease that causes vision loss. The treatment uses a harmless virus to deliver a healthy gene directly into the eye. This could help improve or stabilize their vision. The study will monitor safety and effectiveness over time. This marks a significant advance in treating genetic eye diseases.
Gene Therapy
Gene Therapy for Retinitis Pigmentosa
This trial tests a gene therapy for people with X-linked retinitis pigmentosa. It uses a harmless virus to deliver a healthy gene to eye cells, aiming to improve their function and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating inherited retinal dystrophies, including retinitis pigmentosa.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
This trial is testing a gene therapy that uses a harmless virus to deliver a healthy gene to eye cells. It targets people with X-linked retinitis pigmentosa, aiming to help their eye cells work better and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating retinal diseases, with the first FDA-approved therapy in 2017.
Phase 3 Trials
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Antisense Oligonucleotide
Ultevursen for Vision Impairments
This trial tests a drug called ultevursen, which is injected into the eye, for patients with a specific genetic form of Retinitis Pigmentosa. The drug targets and modifies the genetic mutation causing their vision loss.
Gene Therapy
BIIB111 for Choroideremia & BIIB112 for X-Linked Retinitis Pigmentosa
This trial will compare the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111, with untreated control participants who have exited the STAR (NCT03496012) study. The trial will also compare BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112.
Gene Therapy
Gene Therapy for Retinitis Pigmentosa
This trial tests a gene therapy for people with X-linked retinitis pigmentosa. It uses a harmless virus to deliver a healthy gene to eye cells, aiming to improve their function and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating inherited retinal dystrophies, including retinitis pigmentosa.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
This trial is testing a gene therapy that uses a harmless virus to deliver a healthy gene to eye cells. It targets people with X-linked retinitis pigmentosa, aiming to help their eye cells work better and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating retinal diseases, with the first FDA-approved therapy in 2017.
Trials With No Placebo
Phosphodiesterase Type 5 (PDE5) Inhibitor
Sildenafil for Choroidal Ischemia
This trial is testing if Sildenafil can help patients with certain eye conditions by improving blood flow in the eye. The goal is to slow down vision loss and reduce the need for frequent treatments. Sildenafil, commonly known as Viagra, is primarily used to treat erectile dysfunction but has been studied for its effects on ocular blood flow and potential neuroprotective benefits in various eye conditions.
Stem Cell Therapy
Stem Cell Implantation for Retinitis Pigmentosa
This trial is testing if introducing special cells into the eye is safe for patients with vision loss. The cells might help protect and support the existing nerve cells in the eye, potentially slowing down or stopping vision loss.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Frequently Asked Questions
Introduction to retinitis pigmentosa
What are the top hospitals conducting retinitis pigmentosa research?
When it comes to advancing the understanding and treatment of retinitis pigmentosa, several leading hospitals are making significant strides. In Dallas, the Retina Foundation of the Southwest is at the forefront with five ongoing clinical trials dedicated to this rare eye disorder. With a remarkable total of 20 completed trials since initiating their first study in 2004, this institution has been pivotal in shedding light on retinitis pigmentosa. Meanwhile, in Pittsburgh, the UPMC Eye Center is actively conducting three trials for this condition. Although relatively new in terms of its research endeavors, having started their first trial in 2017, they have already made valuable contributions towards unraveling the mysteries surrounding retinitis pigmentosa.
In Gainesville's Vitreo Retinal Associates center researchers too are focusing much on finding potential treatments for patients suffering from vision loss caused by retinitis pigmentosa where they run three active clinical examinations while keeping track of previously four held medical studies starting from only last year around2020.Universityof Michigan stands out as another formidable player by offering similar approach with holding three ongoing tests among which being no less than pioneers;it was back thereyears ago that itsfirst initiative began specifically addressingretinitispigmentosawhile DukeEyeCenter exhibits equally promising dedication by running additionalthreeactive investigations following footsteps throughfive previous experiments since stepping intothisjourney aimedat tacklingthe diseasefour years earlierin2015.
These esteemed institutions serve as beacons of hope for those affected by retinitis pigmentosa—a progressive and inherited degenerative eye disorder that often leads to severe visual impairment or blindness. Their collective efforts not only pave the way for potential breakthroughs but also underline the commitment and determination within the medical community to provide better care and quality of life for individuals grappling with this challenging condition worldwide.
Which are the best cities for retinitis pigmentosa clinical trials?
When it comes to retinitis pigmentosa clinical trials, several cities are leading the way in research and development. Ann Arbor, Michigan has 8 active trials that investigate treatments such as Genetic: AAV5-RPGR and N-acetylcysteine. Pittsburgh, Pennsylvania also plays a significant role with 7 ongoing studies focused on options like Step 1: SPVN06 dose 1 and Genetic: AAV5-RPGR. Additionally, Gainesville, Florida is actively conducting 7 trials exploring potential breakthroughs including BIIB111 and N-acetylcysteine. These cities offer individuals with retinitis pigmentosa access to cutting-edge clinical trials that bring hope for advancements in care and improved outcomes.
Which are the top treatments for retinitis pigmentosa being explored in clinical trials?
In the realm of retinitis pigmentosa, cutting-edge clinical trials are exploring a range of potential treatments. Notably, N-acetylcysteine has emerged as a promising option, currently being tested in one active trial dedicated to this condition. Another contender is OCU400 High Dose, which also boasts one ongoing trial focused on retinitis pigmentosa. Additionally, researchers are investigating the potential benefits of CNS10-NPC implantation and BS01 through their respective individual trials. As these innovative treatments gain momentum in clinical research since their first listings starting from 2020 onwards, there is hope for improved outcomes for individuals living with retinitis pigmentosa.
What are the most recent clinical trials for retinitis pigmentosa?
Exciting advancements in clinical trials for retinitis pigmentosa offer hope for those affected by this condition. One notable trial is focusing on SPVN06, which has progressed to Phase 2 after showing promising results in Phase 1. Additionally, the OCU400 High Dose trial has reached both Phase 1 and Phase 2 stages, demonstrating its potential as a treatment option. Another study explores Ultevursen's efficacy in treating retinitis pigmentosa, with positive outcomes observed during its progression from Phase 2 to Phase 3. Further research delves into CNS10-NPC implantation as a potential therapeutic intervention at the initial phase of investigation. Finally, MCO-010-High Dose shows promise based on encouraging findings during its advancement through Phase 2 trials. These recent clinical trials offer renewed optimism for individuals living with retinitis pigmentosa and highlight ongoing efforts to find effective treatments for this condition.
What retinitis pigmentosa clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of retinitis pigmentosa, a degenerative eye disease. Notably, Aldeyra Therapeutics successfully concluded a trial for ADX-2191 in July 2022, offering hope for potential therapeutic options. Furthermore, jCyte's investigation into human retinal progenitor cells reached its completion milestone in December 2020. These advancements underscore the ongoing efforts to find effective treatments for retinitis pigmentosa and bring us closer to improving the lives of those affected by this condition.